The new office will be responsible for Amarin’s R&D activities in cardiovascular disease which includes AMR101 for hypertriglyceridemia, planned to enter Phase III in 2009.
Amarin has also announced an expansion of its R&D team with the addition of George Grandolfi as vice president and head of chemistry, manufacturing and controls and Rene Braeckman as vice president and head of development operations.
Thomas Lynch, chairman and CEO of Amarin, said: “The opening of the new office reflects our commitment to the cardiovascular programs and our desire to attract leading experts in the US to our R&D team.”